Literature DB >> 23547215

Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.

Xuli Jerry Zhang1, Ashley Bonner, Marie Hudson, Murray Baron, Janet Pope.   

Abstract

OBJECTIVE: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and causes death. Once lung fibrosis occurs, disease course may become stable or decline. Little is known about risks for progression. We studied SSc-gastroesophageal (GE) involvement in relation to worsening forced vital capacity (FVC) on pulmonary function tests (PFT) to investigate whether it was related to progression. Our objective was to determine whether GE reflux and dysphagia are associated with progressive moderate/severe ILD as measured by PFT over 3 years.
METHODS: The Canadian Scleroderma Research Group is a multicenter SSc database that collects data annually. Using indicators of GE involvement and annual PFT, comparisons were made between no/mild ILD, stable moderate/severe ILD, and progressive moderate/severe ILD groups based on changes of FVC. Multivariate analyses determined associations between GE factors and ILD development and progression.
RESULTS: There were 1043 patients with SSc (mean age 55.7 yrs, mean disease duration 10.8 yrs); one-quarter had pulmonary fibrosis on chest radiograph that was related to FVC percentage predicted (Spearman's rho -0.39; p < 0.01). Physician indicators such as esophageal dysmotility (p = 0.009) and postesophageal dilatation (p = 0.041), and patient indicators such as difficulty swallowing (p = 0.016) and waking up choking (p = 0.026) were associated with low FVC. In comparing progressive and stable moderate/severe FVC (< 70% predicted), early satiety (p = 0.018) and a combination term of postdilatation and choking (p = 0.042) increased risk of progression of ILD. Topoisomerase I was not associated with progression over followup.
CONCLUSION: Symptoms of esophageal dysmotility were associated with worsening FVC in SSc, especially if both need for esophageal dilatation and choking were present.

Entities:  

Keywords:  DYSPHAGIA; GASTROESOPHAGEAL REFLUX DISEASE; INTERSTITIAL LUNG DISEASE; PULMONARY FIBROSIS; SCLERODERMA; SYSTEMIC SCLEROSIS

Mesh:

Year:  2013        PMID: 23547215     DOI: 10.3899/jrheum.120705

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

2.  Predictors of inpatient mortality in patients with systemic sclerosis: a case control study.

Authors:  Shiv T Sehra; Andrew Kelly; Joshua F Baker; Chris T Derk
Journal:  Clin Rheumatol       Date:  2016-04-07       Impact factor: 2.980

3.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

4.  Preoperative Pulmonary Function Tests Predict Aspiration Pneumonia After Gastric Endoscopic Submucosal Dissection.

Authors:  Akihiro Matsumi; Ryuta Takenaka; Chihiro Ando; Yuki Sato; Kensuke Takei; Eriko Yasutomi; Shotaro Okanoue; Shohei Oka; Daisuke Kawai; Junro Kataoka; Koji Takemoto; Hirofumi Tsugeno; Shigeatsu Fujiki; Yoshiro Kawahara
Journal:  Dig Dis Sci       Date:  2017-09-06       Impact factor: 3.199

5.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

Review 6.  Advances in the evaluation and management of esophageal disease of systemic sclerosis.

Authors:  Dustin A Carlson; Monique Hinchcliff; John E Pandolfino
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

7.  Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.

Authors:  Carrie Richardson; Rishi Agrawal; Jungwha Lee; Orit Almagor; Ryan Nelson; John Varga; Michael J Cuttica; Jane D Amico Dematte; Rowland W Chang; Monique E Hinchcliff
Journal:  Semin Arthritis Rheum       Date:  2016-02-26       Impact factor: 5.532

Review 8.  Update on scleroderma-associated interstitial lung disease.

Authors:  Ming-Hui Fan; Carol A Feghali-Bostwick; Richard M Silver
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

9.  Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility.

Authors:  Zsuzsanna H McMahan; Robyn T Domsic; Lei Zhu; Thomas A Medsger; Livia Casciola-Rosen; Ami A Shah
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-08-06       Impact factor: 4.794

10.  Pulmonary Disease Secondary to Reflux Mimicking Interstitial Pneumonia in Systemic Sclerosis: Case Report and Literature Review.

Authors:  Ricardo Azêdo de Luca Montes; Nathalia Mazolli Veiga; Pedro Gemal Lanzieri; Luis Otávio Cardoso Mocarzel
Journal:  Case Rep Rheumatol       Date:  2016-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.